Molecular mechanisms of castration-resistant prostate cancer progression. - Wikidata - awgldk - TriplyDB

Molecular mechanisms of castration-resistant prostate cancer progression.

Molecular mechanisms of castration-resistant prostate cancer progression.

http://www.wikidata.org/entity/Q37630578

about

Androgen receptor molecular biology and potential targets in prostate cancer Oncolytic adenovirus-mediated therapy for prostate cancer Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumour cells Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway.The role of GATA2 in lethal prostate cancer aggressiveness.Intrinsic disorder in the androgen receptor: identification, characterisation and drugability.A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer.The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer ESR1 Gene Polymorphisms and Prostate Cancer Risk: A HuGE Review and Meta-Analysis Androgen receptor in laryngeal carcinoma: could there be an androgen-refractory tumor?Selective roles for cAMP response element-binding protein binding protein and p300 protein as coregulators for androgen-regulated gene expression in advanced prostate cancer cells Castration-resistant prostate cancer: mechanisms, targets, and treatment.Autophagy regulates lipolysis and cell survival through lipid droplet degradation in androgen-sensitive prostate cancer cells Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy.Suppression of prostate epithelial proliferation and intraprostatic progrowth signaling in transgenic mice by a new energy restriction-mimetic agent.Src controls castration recurrence of CWR22 prostate cancer xenografts.Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer.SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer.Mechanisms of androgen receptor activation in castration-resistant prostate cancer Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.Ailanthone: a new potential drug for castration-resistant prostate cancer.Steps in prostate cancer progression that lead to bone metastasis IL-6/IL-6 receptor system and its role in physiological and pathological conditions.Testosterone in prostate cancer: the Bethesda consensus.Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior.Androgen receptor modulators: a marriage of chemistry and biology.Enzalutamide: looking back at its preclinical discovery.Targeting the 5'-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer.A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance.Development of enzalutamide for metastatic castration-resistant prostate cancer.NQO1 suppresses NF-κB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis.Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters.Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST).Proteomics analyses of prostate cancer cells reveal cellular pathways associated with androgen resistance.Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.Androgen Signaling in Prostate Cancer.

P2860

Q24602861-2404BB30-11C3-490C-A5FF-1088C06BF7C7 Q27004796-674F14EA-DB55-48AF-BAFD-7C40A20BD05E Q28288947-57CB32A5-94DE-4CE5-9854-59C2288A0C48 Q28484203-AC4A13FA-B665-4F97-88CB-27C6FE13385E Q31083556-3747BDF2-FFC6-4274-AC2E-FF4444899402 Q33848134-F5D8997D-D805-477A-B554-23C64C4F245E Q33984776-F4E2BAD7-15B1-42FB-B23B-162CCC2DB873 Q34183632-503F3A6F-DE4E-41E4-9B36-D8C7E7D4CA46 Q34189517-A769A8CE-1283-4FCE-AA04-A08599B3364C Q34387852-B20CECC7-1802-404D-B414-B9F93B762DC1 Q34477201-9911B9C0-EB8A-4299-9E9A-8307DFC2E260 Q34785620-80667760-84FB-484A-88F3-7A4A9C672929 Q35608920-85AAEFD3-0940-4E01-9019-FEA56554EA21 Q35763204-7AC152D2-10A0-4398-98C1-76454207B0EC Q35864027-6C2C95B7-7139-4A2A-A9AF-04D3C7C3A1FF Q36162068-82BE0ABC-1D69-451B-8F00-4E197A9F6B68 Q36738996-43A976F3-3CF9-45D5-B4A2-E936A996A234 Q37127302-3F68B3FD-76A6-4742-9934-8ED7D0BE54B7 Q37328622-A29C9846-4231-496A-B891-042F81031D53 Q37481145-4A8604D8-B24D-4799-B34A-28B6FF527BC4 Q37508596-94A2A9CE-4F5C-4E72-BC32-C10739E4D781 Q37533348-55FBA77D-0B1C-4C6C-8A3B-F6628D839FD0 Q37628940-3A81CFE1-4F89-42EA-93B8-54B578E0AE4E Q37641718-EC8DE332-FA92-40E3-8A58-900CFF45E1BF Q37680134-720045EC-73A9-4A96-92F7-04EA580C3CCB Q37848782-37EEAFBC-DDD7-4009-AD69-510CA9B1BA29 Q37949664-1B80111F-D633-4C3F-BEC7-5D8D2D4B95C9 Q37963010-26698E33-3F94-4863-9206-BC04B3BBB36A Q37970017-2E8E1663-F545-48E4-8EE0-701B5E2DD664 Q38116575-D85C81C0-F366-4A65-8830-7AB260EDD56F Q38211257-C383FB6B-A09D-47E0-85F3-EDA0216C8C1D Q38323902-7E0399DA-FB72-49B5-ABDE-109710378C04 Q38434103-8FCF8E48-4A0A-42A8-82E2-5715D0EFEE0E Q38589130-09351E50-B8A2-4ED7-8372-FF33CB6826AA Q38965814-632A23E5-FC58-4C38-8FCE-34A1D797906A Q38983205-BD08D568-DA9D-4338-B947-67C4D4C6CED2 Q38995864-41D34CF5-45F5-4D05-A36F-18B1E3EB3DC6 Q39002801-A058673E-9653-41C3-B613-B4D2E187B113 Q39139830-F129EE13-AF76-4BF2-8686-22556E9312A0 Q39227656-5231BE71-9B85-4491-BED2-D203AEED3955

P2860

Molecular mechanisms of castration-resistant prostate cancer progression.

http://www.wikidata.org/entity/Q37630578

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Molecular mechanisms of castration-resistant prostate cancer progression.

@en

Molecular mechanisms of castration-resistant prostate cancer progression.

@nl

type

label

Molecular mechanisms of castration-resistant prostate cancer progression.

@en

Molecular mechanisms of castration-resistant prostate cancer progression.

@nl

prefLabel

Molecular mechanisms of castration-resistant prostate cancer progression.

@en

Molecular mechanisms of castration-resistant prostate cancer progression.

@nl

P1433

Q37630578-964088FB-23A6-4A23-82D7-858F6DAB5201

P1476

Q37630578-15FCEABC-7567-4732-A945-60BF4555DBE8

P2093

Q37630578-14EB40F1-165B-492D-BD80-70DCD980DA56

Q37630578-8EE5F3F9-13E7-40C8-B683-5B75016315E5

P2860

Q37630578-0263CFBE-B14F-4742-B90E-4FA2DA26F561

Q37630578-1944D4A5-35FB-4179-A5F0-D2B72622F6C9

Q37630578-1968040B-C534-48AF-B771-87B0D438643B

Q37630578-1A94A1AF-246C-421A-A429-49BD2B66AB30

Q37630578-20CF5A03-7AD5-4E0B-AEAA-8F471275AF23

Q37630578-22D78CAC-1306-4937-9776-3D497D672C85

Q37630578-29DE3053-70B7-4B92-A917-02ACD45FE1BA

Q37630578-2F60A7EE-2407-49BE-B293-A4A03214897E

Q37630578-3C78F4D6-CDB9-4EB0-AD20-568EA0481938

Q37630578-41CB7140-EA3E-47D2-85B8-8E477FC2D8D0

P304

Q37630578-0BEF740A-C23B-42D7-83FD-F658B302313E

P31

Q37630578-33D24887-A607-4FF0-9807-C8CE76E8FF8B

P356

Q37630578-E3CDD2FF-B6E3-480B-923E-FA54CC59037B

P407

Q37630578-3338B4AE-57D6-4991-84F4-413177E647D4

P433

Q37630578-1F75D23B-6349-4D7F-853B-731A5CDF1411

P478

Q37630578-FF14D959-86FE-4B97-AB35-D7A232BB6983

P577

Q37630578-EEB22FC5-0381-44F3-9AA3-ED6FC5D5077C

P5875

Q37630578-B0EFFE14-3C24-4AA8-BC55-CD75AB2AD664

P698

Q37630578-E0F89E27-340E-4721-B385-A67AA8ED2BCC

P932

Q37630578-5CA218F8-A8FA-4621-8142-4FECE2FD8F49

P356

P1433

Future Oncology

P1476

Molecular mechanisms of castration-resistant prostate cancer progression.

@en

P2093

Allen C Gao

http://www.w3.org/2001/XMLSchema#string

Smitha S Dutt

http://www.w3.org/2001/XMLSchema#string

P2860

Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells

Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase

Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase

The development of androgen-independent prostate cancer

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

What might a stromal response mean to prostate cancer progression?

Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.

P304

1403-1413

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.09.117

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38079815

http://www.w3.org/2001/XMLSchema#string

P698

19903068

http://www.w3.org/2001/XMLSchema#string

P932

3041149

http://www.w3.org/2001/XMLSchema#string